Adcytherix (NASDAQ: ADTX) Initiates Phase 1 Trial of ADCX-020 and Enhances Leadership Team
Market Overview Adcytherix (NASDAQ: ADTX) has taken a significant step in advancing its oncology pipeline with the dosing of the first patient in its Phase 1 clinical trial for ADCX-020. This milestone marks the company’s continued commitment to developing innovative antibody-drug conjugates aimed at addressing unmet needs in cancer treatment. Following this development, ADTX stock has drawn interest from investors focusing on biopharmaceutical innovation. The launch of the trial positions…
